Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study.

ABSTRACT:

Background

Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy are now standard of care in the first- or second-line settings for hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) patients with advanced / metastatic breast cancer (ABC/MBC). Abemaciclib was first authorised in the United Kingdom (UK) in 2018 via patient access schemes before approval for routine use. This study assessed the treatment patterns and outcomes of abemaciclib in combination with endocrine therapy in a real-world setting.

Methods

This was an observational, multi-centre retrospective chart review of women in the UK with HR+, HER2- ABC/MBC treated with abemaciclib plus endocrine therapy during 07/2021 to 05/2022 with [Formula: see text]3 months' follo

SUBMITTER: King J 

PROVIDER: S-EPMC12275406 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature